Compound class:
Synthetic organic
Comment: CIAC001 is a cannabidiol (CBD) analogue [1]. Its molecular target is reported as pyruvate kinase M2 (PKM2). CIAC001 is hypothesised to stabilise PKM2 tetramers within the cytosol, which reduces monomer translocation to the nucleus and thus attenuates neuronal inflammation. This mechanism is proposed as a therapeutic strategy to treat opioid addiction, by targeting opioid-caused neuroinflammation.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
(1′R,2′R)-4-(1-(2H-1,2,3-Triazol-2-yl)ethyl)-5′-methyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-2,6-diol |
Database Links ![]() |
|
GtoPdb PubChem SID | 485206034 |
PubChem CID | 168510601 |
Search Google for chemical match using the InChIKey | AGJUGOFAIPQXTD-MWSTZMHHSA-N |
Search Google for chemicals with the same backbone | AGJUGOFAIPQXTD |
UniChem Compound Search for chemical match using the InChIKey | AGJUGOFAIPQXTD-MWSTZMHHSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | AGJUGOFAIPQXTD-MWSTZMHHSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
CIAC001 (links to external site)
Cat. No. HY-155850 |